150 related articles for article (PubMed ID: 35700798)
1. Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells.
Rahman MK; Al-Zubaidi Y; Bourget K; Chen Y; Tam S; Zhou F; Murray M
J Pharm Sci; 2022 Aug; 111(8):2180-2190. PubMed ID: 35700798
[TBL] [Abstract][Full Text] [Related]
2. The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
Tam S; Al-Zubaidi Y; Rahman MK; Bourget K; Zhou F; Murray M
Pharmacol Rep; 2022 Oct; 74(5):998-1010. PubMed ID: 35908023
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
4. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
5. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
8. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
9. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley DA; Arrowsmith ER; Daniel BR; Eakle J; Brufsky A; Drosick DR; Kudrik F; Bosserman LD; Keaton MR; Goble SA; Bubis JA; Priego VM; Pendergrass K; Manalo Y; Bury M; Gravenor DS; Rodriguez GI; Inhorn RC; Young RR; Harwin WN; Silver C; Hainsworth JD; Burris HA
Breast Cancer Res Treat; 2017 Aug; 164(3):649-658. PubMed ID: 28508185
[TBL] [Abstract][Full Text] [Related]
10. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
11. Novel cytotoxic agents: epothilones.
Goodin S
Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
15. Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.
Rak Tkaczuk KH
Breast Cancer (Auckl); 2011 Jan; 5():1-14. PubMed ID: 21494397
[TBL] [Abstract][Full Text] [Related]
16. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
[TBL] [Abstract][Full Text] [Related]
17. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
18. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.
Rugo HS; Roche H; Thomas E; Chung HC; Lerzo GL; Vasyutin I; Patel A; Vahdat L
Clin Breast Cancer; 2018 Dec; 18(6):489-497. PubMed ID: 30153978
[TBL] [Abstract][Full Text] [Related]
20. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
